TRDA - Entrada Therapeutics Inc
IEX Last Trade
17.74
0.240 1.353%
Share volume: 177,913
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$17.50
0.24
1.37%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-07 | 2023-03-06 | 2023-05-10 | 2023-08-08 | 2023-11-07 | 2024-03-13 | 2024-05-07 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 25.260 M | 18.170 M | 43.735 M | 41.848 M | 59.120 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 25.260 M | 18.170 M | 43.735 M | 41.848 M | 59.120 M | |
| nan% | nan% | inf% | -28.07% | 140.70% | -4.31% | 41.27% | |||
| Operating expenses | 23.582 M | 25.936 M | 25.579 M | 31.040 M | 34.469 M | 29.723 M | 36.943 M | 38.007 M | |
| Selling general and admin | 7.334 M | 6.978 M | 9.894 M | 7.938 M | 8.169 M | 7.532 M | 8.652 M | 9.399 M | |
| Research and development | 16.248 M | 18.958 M | 15.685 M | 23.102 M | 26.300 M | 22.191 M | 28.291 M | 28.608 M | |
| Total expenses | 23.582 M | 25.936 M | 25.579 M | 31.040 M | 34.469 M | 29.723 M | 36.943 M | 38.007 M | |
| 9.98% | -1.38% | 21.35% | 11.05% | -13.77% | 24.29% | 2.88% | |||
| Operating income | -23.582 M | -25.936 M | -25.579 M | -5.780 M | -16.299 M | 14.012 M | 4.905 M | 21.113 M | |
| Ebit | -23.582 M | -25.936 M | -25.579 M | -5.780 M | -16.299 M | 14.012 M | 4.905 M | 21.113 M | |
| Pretax income | -23.179 M | -25.137 M | -24.629 M | -3.123 M | -12.081 M | 18.063 M | 9.197 M | 25.327 M | |
| 8.45% | -2.02% | -87.32% | 286.84% | -249.52% | -49.08% | 175.38% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 3.551 M | 13.847 M | -17.398 M | 18.741 M | 1.831 M | |
| Net income basic | -23.179 M | -25.137 M | -24.629 M | -6.674 M | -25.928 M | 35.461 M | -9.544 M | 23.496 M | |
| -8.45% | 2.02% | 72.90% | -288.49% | 236.77% | -126.91% | 346.19% | |||
| Net income | -23.179 M | -25.137 M | -24.629 M | -6.674 M | -25.928 M | 35.461 M | -9.544 M | 23.496 M | |
| -8.45% | 2.02% | 72.90% | -288.49% | 236.77% | -126.91% | 346.19% |